Renata (DHA:RENATA) Other Current Receivables: BDT464 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:RENATA Renata PLC DHA:RENATA
85 GF Score
Price BDT474.10
GF Value BDT817.57
Valuation Significantly Undervalued
! 8 Warning Signs
View Full Analysis

What is Renata Other Current Receivables?

Renata DHA:RENATA +0.15% 85 Other Current Receivables is BDT464 Mil as of Mar. 2026. GuruFocus rates DHA:RENATA with a GF Score™ of 85/100 and a GF Value™ of BDT817.57 (Significantly Undervalued). The stock has 8 warning signs investors should review.

Renata's Other Current Receivables for the quarter that ended in Mar. 2026 was BDT464 Mil.

Renata's quarterly Other Current Receivables increased from Sep. 2025 (BDT497.10 Mil) to Dec. 2025 (BDT601.27 Mil) but then stayed the same from Dec. 2025 (BDT601.27 Mil) to Mar. 2026 (BDT463.74 Mil).

Renata's annual Other Current Receivables increased from Jun. 2023 (BDT605.84 Mil) to Jun. 2024 (BDT730.79 Mil) but then declined from Jun. 2024 (BDT730.79 Mil) to Jun. 2025 (BDT430.82 Mil).

Renata Other Current Receivables Related Terms

Renata Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Renata's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renata Other Current Receivables Chart

Renata Annual Data
Trend Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 273.06 -57.06 605.84 730.79 430.82

Renata Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 233.85 430.82 497.10 601.27 463.74
DHA:RENATA
85GF Score
Renata PLC DHA:RENATA
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Renata Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of BDT464 Mil mean?
Renata (DHA:RENATA) has a Other Current Receivables of BDT464 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Renata and its competitors.
Is Renata's Other Current Receivables too high?
Renata's current Other Current Receivables is BDT464 Mil. Overall, Renata has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Renata's Other Current Receivables compare to ZTS and UTHR?
Renata's Other Current Receivables of BDT464 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Renata and its competitors. Renata's current Other Current Receivables is BDT464 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renata stock overvalued right now?
Based on GuruFocus' analysis, Renata (DHA:RENATA) is currently considered Significantly Undervalued. The stock's GF Value™ is BDT817.57, compared to a current price of BDT474.10 — trading 42% below its estimated fair value. The current Other Current Receivables is BDT464 Mil. Renata's overall GF Score™ is 85/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Renata (DHA:RENATA), the current Other Current Receivables is BDT464 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Renata (DHA:RENATA) Overvalued in 2026?

Based on GuruFocus' analysis, Renata stock appears to be undervalued. The current stock price of BDT474.10 is trading 42% below its estimated GF Value™ of BDT817.57. GuruFocus considers Renata to be Significantly Undervalued.

Key valuation signals for DHA:RENATA:

  • Other Current Receivables: BDT464 Mil
  • GF Value™: BDT817.57 vs. price of BDT474.10 (42% below fair value)
  • GF Score™: 85/100 with 8 warning signs

No single metric tells the full story. See the DHA:RENATA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Renata Business Description

Address Plot Number 1, Milk Vita Road, Section-7, GPO Box No. 303, Mirpur, Dhaka, BGD, 1216
Renata PLC is a Bangladesh based pharmaceutical company. It is engaged in the manufacturing, marketing, and distribution of Human Pharmaceuticals, Animal Health Medicines, Nutritionals, and Vaccines. It manufactures various pharmaceutical products including Beconex Zi Syrup, Cabolin Tablet, Flontin Tablet, Ivana Tablet, and others. Some of the animal health products offered by the company are Doxivet Powder, Fevenil Injection, Diadin Bolus, Renamet Tablet, and others. The company operates in Bangladesh and sells its products locally and internationally.
85GF Score

Get the complete analysis for DHA:RENATA

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT474.10
Price
BDT817.57
GF Value